Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
3.540
-0.170 (-4.58%)
May 13, 2026, 11:27 AM EDT - Market open
Exagen Revenue
Exagen had revenue of $17.31M in the quarter ending March 31, 2026, with 11.67% growth. This brings the company's revenue in the last twelve months to $68.38M, up 20.55% year-over-year. In the year 2025, Exagen had annual revenue of $66.58M with 19.65% growth.
Revenue (ttm)
$68.38M
Revenue Growth
+20.55%
P/S Ratio
1.31
Revenue / Employee
$310,832
Employees
220
Market Cap
85.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.58M | 10.93M | 19.65% |
| Dec 31, 2024 | 55.64M | 3.09M | 5.89% |
| Dec 31, 2023 | 52.55M | 6.99M | 15.33% |
| Dec 31, 2022 | 45.56M | -2.74M | -5.66% |
| Dec 31, 2021 | 48.30M | 6.32M | 15.07% |
| Dec 31, 2020 | 41.98M | 1.59M | 3.93% |
| Dec 31, 2019 | 40.39M | 7.95M | 24.50% |
| Dec 31, 2018 | 32.44M | 5.63M | 21.01% |
| Dec 31, 2017 | 26.81M | 8.86M | 49.38% |
| Dec 31, 2015 | 17.95M | 6.28M | 53.87% |
| Dec 31, 2014 | 11.66M | 8.61M | 281.77% |
| Dec 31, 2013 | 3.06M | 2.13M | 229.91% |
| Dec 31, 2012 | 926.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| Castle Biosciences | 339.92M |
| Fulgent Genetics | 320.35M |
| MDxHealth | 107.88M |
| FONAR | 105.34M |
| Biodesix | 96.10M |
| Prenetics Global | 92.39M |
| Burning Rock Biotech | 77.14M |
XGN News
- 1 day ago - Exagen price target lowered to $8 from $9 at BTIG - TheFly
- 1 day ago - Exagen reports Q1 EPS (17c), consensus (25c) - TheFly
- 1 day ago - Exagen backs FY26 revenue view $70M-$73M, consensus $71.27M - TheFly
- 2 days ago - Exagen Earnings Call Transcript: Q1 2026 - Transcripts
- 2 days ago - Exagen Inc. Reports First Quarter 2026 Results - GlobeNewsWire
- 16 days ago - Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026 - GlobeNewsWire
- 23 days ago - Exagen price target lowered to $8 from $10 at Canaccord - TheFly
- 2 months ago - Exagen price target lowered to $10 from $12 at Craig-Hallum - TheFly